Citations

Clear

278 citation(s) found for "Sy, Ethan".

Cardiac myosin and the Th17 immunophenotype in human autoimmune myocarditis (HUM1P.252)
Cunningham, Madeleine W. , Myers, J. Martin, Kem, David C. , Stavrakis, Stavros , Shevach, Ethan M. , Stoner, Julie A., Cox, Carol J. , Cooper, Leslie T. , Fairweather, DeLisa

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 194 | Issue: 1_Supplement | Pages: 52.1-52.1

10.4049/jimmunol.194.supp.52.1 Get It

Abstract The immunopathogenesis of autoimmune myocarditis and dilated cardiomyopathy (DCM) in humans is unpredictable and pathogenic mechanisms undefined. The aim was to investigate potential autoimmune mechanisms in human autoimmune myocarditis and heart failure. Our evidence for a Th17 immunophenotype in human myocarditis/DCM(n=40) included reduced CD4+CD25+FoxP3+ Tregulatory cells(0.0006), elevated Th17 cells(0.0008) and increased Th17-promoting cytokines(IL-6 and TGF-beta). Th1(IFNγ+) cells were not significantly elevated(p=0.7184). IL-6(<0.0001), TGF-beta(0.0001), IL-23(0.0003), and GM-CSF+ T cells(0.0006) were significantly elevated. IL-17A+ cells were prevalent in biopsies from human myocarditis, non-recovery associated with persistence of IL-17A cytokines and heart failure associated with elevated Th17 cells in peripheral blood. To identify a potential mechanism to promote a Th17 pro-inflammatory pathogenesis in the heart, novel TLR ligands of human cardiac myosin (HCM) (peptides S2-16 and S2-28) promoted myocarditic PBMCs/CD14+ monocytes to produce Th17 cytokines(IL-23 p=0.0289; IL-6,TGF-beta p<0.0001). TLR ligand stimulation of PBMCs/ monocytes was abrogated by antibodies blocking TLR2, IL-6, IL-17A/23, and GM-CSF. Our translational study suggested human myocarditis/DCM may be controlled by a Th17 phenotype including reduced Treg, elevated Th17 cells, and pro-inflammatory and pro-fibrotic Th17 cytokines triggered by cardiac myosin TLR ligands potentially released from heart.
CELL SENESCENCE IS A FEATURE AND MODULATOR OF THE AGED INFLAMMATORY BRAIN CELL LANDSCAPE
Carver, Chase, Pearsall, Vesselina, Atkinson, Elizabeth J. , Clarkson, Benjamin D. , Grund, Ethan M. , Schafer, Marissa , Zhang, Xu , LeBrasseur, Nathan K.

Mayo Clinic

Innovation in Aging | December 20, 2022 | Volume: 6 | Issue: Supplement_1 | Pages: 195-196

10.1093/geroni/igac059.781 Get It

Abstract New strategies to preserve cognitive function could broadly benefit the aging population. Cellular senescence is a hypothesized mediator of inflammation-related tissue dysfunction in aging. Using single-cell RNA-sequencing, we discovered an age-related brain myeloid population exhibiting overlapping senescent and disease-associated activation signatures, including upregulation of chemoattractant factors. We confirmed senescent brain myeloid cells promote peripheral immune cell chemotaxis in vitro. Through mass cytometry, we demonstrate age- and sex-dependent increases in activated resident and infiltrating brain immune cells are reduced through systemic targeting of p16-positive senescent cells, which is associated with improvements in executive function and spatial learning tasks. Our high-dimensional results reveal dynamic remodeling of the age-dependent brain immune cell landscape and implicate senescent cell targeting as a strategy to counter inflammatory changes and cognitive decline.
Development and Examination of a Trainee-Led ECHO Autism Network for Rural Healthcare Providers
Cardon, Garrett , Dahl, Ethan , Diaków, Diana M. , Neumann, Alyssa A. , Mallone, Kalley, Permar, Haley, Benallie, Kandice J. , Haverkamp, Cassity R. , Lindsey, Rebecca A., Romero, Sebastian , Sherman, Whitney M., Hardesty, Canyon, Carbone, Paul S. , Gabrielsen, Terisa P. , Clark, Taylor

Mayo Clinic

Journal of Educational and Psychological Consultation | December 5, 2022 | Volume: 33 | Issue: 4 | Pages: 393-420

10.1080/10474412.2022.2151013 Get It

Time to cancer treatment and reproductive outcomes after fertility preservation among adolescent and young adult women with cancer
Meernik, Clare , Engel, Stephanie M. , Baggett, Christopher D. , Wardell, Ally, Zhou, Xi , Ruddy, Kathryn J. , Wantman, Ethan, Baker, Valerie L. , Mersereau, Jennifer E. , Smitherman, Andrew B. , Nichols, Hazel B. , Smitherman, Andrew B , Nichols, Hazel B , Wardell, Ally, Luke, Barbara , Cai, Jianwen , Olshan, Andrew F.

Mayo Clinic

Cancer | November 1, 2022 | Volume: 129 | Issue: 2 | Pages: 307-319

10.1002/cncr.34520 | PMID 36316813 Get It

AbstractBackgroundFertility preservation (FP) may be underused after cancer diagnosis because of uncertainty around delays to cancer treatment and subsequent reproductive success.MethodsWomen aged 15 to 39 years diagnosed with cancer between 2004 and 2015 were identified from the North Carolina Central Cancer Registry. Use of assisted reproductive technology (ART) after cancer diagnosis between 2004 and 2018 (including FP) was assessed through linkage to the Society for Assisted Reproductive Technology. Linear regression was used to examine time to cancer treatment among women who did (n = 95) or did not (n = 469) use FP. Modified Poisson regression was used to estimate risk ratios (RRs) and 95% CIs for pregnancy and birth based on timing of ART initiation relative to cancer treatment (n = 18 initiated before treatment for FP vs n = 26 initiated after treatment without FP).ResultsThe median time to cancer treatment was 9 to 33 days longer among women who used FP compared with women who did not, matched on clinical factors. Women who initiated ART before cancer treatment may be more likely to have a live birth given pregnancy compared with women who initiated ART after cancer treatment (age‐adjusted RR, 1.47; 95% CI, 0.98‐2.23), though this may be affected by the more frequent use of gestational carriers in the former group (47% vs 20% of transfer cycles, respectively).ConclusionsFP delayed gonadotoxic cancer treatment by up to 4.5 weeks, a delay that would not be expected to alter prognosis for many women. Further study of the use of gestational carriers in cancer populations is warranted to better understand its effect on reproductive outcomes.
APOBEC Mutational Signatures in Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy
Sammons, Sarah , Raskina, Kira , Danziger, Natalie , Alder, Laura , Schrock, Alexa B. , Venstrom, Jeffrey M., Knutson, Keith L. , Thompson, E. Aubrey , McGregor, Kim, Sokol, Ethan S. , Chumsri, Saranya , Sokol, Ethan , Sammons, Sarah L , Danziger, Natalie , Knutson, Keith L.

Mayo Clinic

JCO Precision Oncology | October 31, 2022 | Volume: No volume available | Issue: 6 | Pages: No page available

10.1200/po.22.00149 | PMID 36315915 Get It

PURPOSE APOBEC mutagenesis underlies somatic evolution and accounts for tumor heterogeneity in several cancers, including breast cancer (BC). In this study, we evaluated the characteristics of a real-world cohort for time-to-treatment discontinuation (TTD) and overall survival on CDK4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) and immune checkpoint inhibitors. METHODS Comprehensive genomic profiling results from 29,833 BC samples were analyzed for tumor mutational burden and APOBEC signatures. For clinical outcomes, a deidentified nationwide (United States–based) BC Clinico-Genomic Database (CGDB) was evaluated with log-rank and Cox models. Patients with hormone receptor–positive (HR+) human epidermal growth factor receptor 2–negative (HER2–) BC who received first-line ET and CDK4/6i were included. Eligible patients from Mayo Clinic and Duke University were HR+ HER2– BC with sequencing data between September 2013 and July 2020. RESULTS Of 29,833 samples sequenced, 7.9% were APOBEC+ with a high rate in invasive lobular carcinoma (16.7%) and in metastatic tumors (9.7%) relative to locally biopsied BC (4.3%; P < .001). In CGDB, 857 patients with HR+ HER2– BC received ET plus CDK4/6i in the first line. APOBEC+ patients had significantly shorter TTD on ET plus CDK4/6i than APOBEC– patients, 7.8 (95% CI, 4.3 to 14.6) versus 12.4 months (95% CI, 11.2 to 14.1; hazard ratio, 1.6; 95% CI, 1.03 to 2.39; P = .0036). Clinical benefit to immune checkpoint inhibitors was observed in HR+ HER2–, APOBEC+, tumor mutational burden–high patients, with four of nine CGDB patients (TTD 0.3-11.3 months) and four of six patients in Duke/Mayo cohorts (TTD 0.9-40.5 months) with a TTD of ≥ 3 months. CONCLUSION APOBEC+ HR+ HER2– patients had shorter TTD on first-line ET plus CDK4/6i relative to APOBEC– patients. Further research is needed to optimize the treatment of APOBEC+ HR+ HER2– BC and to investigate the efficacy of immunotherapeutic strategies in this population.
A noncoding single-nucleotide polymorphism at 8q24 drives IDH1 -mutant glioma formation
Yanchus, Connor , Drucker, Kristen , Kollmeyer, Thomas M. , Tsai, Ricky , Winick‐Ng, Warren , Liang, Minggao , Malik, Ahmad , Pawling, Judy , Lorenzo, Silvana B. De, Ali, Asma, Decker, Paul A. , Kosel, Matt, Panda, Arijit , Al‐Zahrani, Khalid N. , Jiang, Lingyan , Browning, Jared , Lowden, Christopher , Hernández, J. Javier , Gosio, Jessica , Loganathan, Sampath K. , Berman, Jacob M. , Trcka, Daniel , Michealraj, Kulandaimanuvel Antony , Fortin, Jérôme, Carson, Brittany B. , Hollingsworth, Ethan W. , Jacinto, Sandra , Mazrooei, Parisa, Zhou, Lily , Elia, Andrew , Lupien, Mathieu , Murphy, Daniel J. , Wang, Liguo , Abyzov, Alexej , Dennis, James W. , Maass, Philipp G. , Wrensch, Margaret , Mak, Tak W. , Visel, Axel , Wrana, Jeffrey L. , Zadeh, Gelareh , Eckel‐Passow, Jeanette E. , Attisano, Liliana , Pombo, Ana , Kvon, Evgeny Z. , Jenkins, Robert B. , Schramek, Daniel , Drucker, Kristen L , De Lorenzo, Silvana B, Kosel, Matt L, Browning, Jared W L , Lowden, Chris , Hernandez, J Javier , Ahmed, Musaddeque , Loganathan, Sampath Kumar , Berman, Jacob , Trcka, Daniel , Hollingsworth, Ethan W , Elia, Andrew , Lupien, Mathieu , He, Housheng Hansen , Wang, Liguo , Abyzov, Alexej , Dennis, James W , Maass, Philipp G , Wilson, Michael D , Wrensch, Margaret , Mak, Tak , Pennacchio, Len A , Dickel, Diane E , Visel, Axel , Wrana, Jeffrey , Dirks, Peter , Eckel-Passow, Jeanette E , Attisano, Liliana , Pombo, Ana , Ida, Cristiane M , Kvon, Evgeny Z , Jenkins, RB , Schramek, Daniel , Kollmeyer, Thomas , Murphy, Daniel J , Decker, Paul A. , Kosel, Matthew , Geuenich, Michael J. , Ahmed, Musaddeque , He, Housheng Hansen , Campbell, Kieran R. , Wilson, Michael D. , Lachance, Daniel Honore , Wiencke, John K. , Taylor, Michael D. , Ida, Cristiane M.

Mayo Clinic

Science | October 6, 2022 | Volume: 378 | Issue: 6615 | Pages: 68-78

10.1126/science.abj2890 | PMID 36201590 Get It

Establishing causal links between inherited polymorphisms and cancer risk is challenging. Here, we focus on the single-nucleotide polymorphism rs55705857, which confers a sixfold greater risk of isocitrate dehydrogenase ( IDH) –mutant low-grade glioma (LGG). We reveal that rs55705857 itself is the causal variant and is associated with molecular pathways that drive LGG. Mechanistically, we show that rs55705857 resides within a brain-specific enhancer, where the risk allele disrupts OCT2/4 binding, allowing increased interaction with the Myc promoter and increased Myc expression. Mutating the orthologous mouse rs55705857 locus accelerated tumor development in an Idh1 R132H -driven LGG mouse model from 472 to 172 days and increased penetrance from 30% to 75%. Our work reveals mechanisms of the heritable predisposition to lethal glioma in ~40% of LGG patients.
A randomized controlled trial of routine financial toxicity screening via electronic patient-reported outcomes (AFT-39).
Blinder, Victoria , Deal, Allison M. , Ginos, Brenda, Jansen, Jennifer , Henson, Sydney, Carr, Philip, Rogak, Lauren J. , Weiss, Anna , Rapperport, Anna, Spears, Patricia A. , Gany, Francesca , Basch, Ethan , Deal, Allison , Jansen, Jennifer , Dueck, Amylou C. , Mazza, Gina L , Schrag, Deborah , Basch, Ethan

Mayo Clinic

Journal of Clinical Oncology | September 30, 2022 | Volume: 40 | Issue: 28_suppl | Pages: 180-180

10.1200/jco.2022.40.28_suppl.180 Get It

180 Background: Financial toxicity affects 20% of cancer survivors and is associated with decreased treatment adherence and poor clinical outcomes. No large-scale programs have been implemented to mitigate financial toxicity among patients undergoing cancer treatment. We evaluated the effect of monthly patient-reported financial toxicity screening as part of a larger digital monitoring intervention. Methods: PRO-TECT (AFT-39) is a cluster-randomized trial of patients undergoing systemic therapy for metastatic cancer. Practices were randomized 1:1 to digital symptom monitoring with patient-reported outcomes (“PRO practices”) or usual care (“control practices”). Digital monitoring consisted of between-visit online or automated telephone patient surveys containing symptom, functioning, and financial toxicity screening questions for up to one year, with automated alerts sent to practice nurses for concerning survey scores. Clinical team actions in response to alerts were not mandated. The primary outcome of this analysis was development or worsening of financial difficulties, assessed via the EORTC QLQ-C30 (“Has your physical condition or medical treatment caused you financial difficulties?”), at any time compared to baseline. A randomly selected subset of patients and nurses were interviewed about their experiences with the intervention. Results: 1,191 patients were enrolled (593 PRO; 598 control) at 52 US community oncology practices. Overall, 30.2% of patients treated at practices that received the intervention developed, or experienced worsening of, financial difficulties, compared to 39.0% of patients treated at control practices (p = 0.01). Patients and nurses interviewed stated that financial toxicity screening identified patients for financial counseling who otherwise would be reluctant to seek, or unaware of the availability of, assistance. Conclusions: Screening for financial toxicity as part of routine digital patient monitoring with PROs reduces the development, or worsening, of financial difficulties among patients undergoing systemic cancer therapy. Clinical trial information: NCT03249090.
Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
Joseph‐Mathurin, Nelly , Li, Yan , McCullough, Austin , Hofmann, Carsten, Wojtowicz, Jakub , Park, Ethan, Wang, Guoqiao , Preboske, Gregory M., Gordon, Brian A. , Chen, Charles D., Flores, Shaney , Aggarwal, Neelum T. , Berman, Sarah , Bird, Thomas D., Borowski, Bret, Chhatwal, Jasmeer P. , Clarnette, Roger, Fagan, Anne M. , Farlow, Martin R. , Fox, Nick C. , Gauthier, Serge , Hassenstab, Jason , Hobbs, Diana A. , Holdridge, Karen C. , Hornbeck, Russ C. , Jiménez‐Velázquez, Ivonne Z. , Klein, Gregory , Xiong, Chengjie , Mancini, Michele , McKay, Nicole S. , Mummery, Catherine J. , Ringman, John M. , Snider, B. Joy, Suzuki, Kazushi , Yaari, R. , Perrin, Richard J. , Bateman, Randall J. , Salloway, Stephen , Clifford, David B., Unit, For the Dominantly Inherited Alzheimer Network Trials, Wang, Qing , Gordon, Brian A , Chen, Charles D , Jucker, Mathias , Ringman, John M , Salloway, Steve , Benzinger, Tammie L S , Bateman, Randall J , Joseph-Mathurin, Nelly , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Berman, Sarah , Llibre‐Guerra, Jorge J. , Li, Yan, Wáng, Qīng , Black, Sandra E. , Brooks, William S. , Cruchaga, Carlos , Honig, Lawrence S. , Hsiung, Ging‐Yuek Robin , Jack, Clifford R. , Masellis, Mario , Shimada, Hiroyuki , Wallon, David , Xiong, Chengjie , McDade, Eric , Benzinger, Tammie L.S. , Unit, For the Dominantly Inherited Alzheimer Network Trials

Mayo Clinic

Annals of Neurology | September 24, 2022 | Volume: 92 | Issue: 5 | Pages: 729-744

10.1002/ana.26511 | PMID 36151869 Get It

ObjectiveTo determine the characteristics of participants with amyloid‐related imaging abnormalities (ARIA) in a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease (DIAD).Methods142 DIAD mutation carriers received either gantenerumab SC (n = 52), solanezumab IV (n = 50), or placebo (n = 40). Participants underwent assessments with the Clinical Dementia Rating® (CDR®), neuropsychological testing, CSF biomarkers, β‐amyloid positron emission tomography (PET), and magnetic resonance imaging (MRI) to monitor ARIA. Cross‐sectional and longitudinal analyses evaluated potential ARIA‐related risk factors.ResultsEleven participants developed ARIA‐E, including 3 with mild symptoms. No ARIA‐E was reported under solanezumab while gantenerumab was associated with ARIA‐E compared to placebo (odds ratio [OR] = 9.1, confidence interval [CI][1.2, 412.3]; p = 0.021). Under gantenerumab, APOE‐ɛ4 carriers were more likely to develop ARIA‐E (OR = 5.0, CI[1.0, 30.4]; p = 0.055), as were individuals with microhemorrhage at baseline (OR = 13.7, CI[1.2, 163.2]; p = 0.039). No ARIA‐E was observed at the initial 225 mg/month gantenerumab dose, and most cases were observed at doses >675 mg. At first ARIA‐E occurrence, all ARIA‐E participants were amyloid‐PET+, 60% were CDR >0, 60% were past their estimated year to symptom onset, and 60% had also incident ARIA‐H. Most ARIA‐E radiologically resolved after dose adjustment and developing ARIA‐E did not significantly increase odds of trial discontinuation. ARIA‐E was more frequently observed in the occipital lobe (90%). ARIA‐E severity was associated with age at time of ARIA‐E.InterpretationIn DIAD, solanezumab was not associated with ARIA. Gantenerumab dose over 225 mg increased ARIA‐E risk, with additional risk for individuals APOE‐ɛ4(+) or with microhemorrhage. ARIA‐E was reversible on MRI in most cases, generally asymptomatic, without additional risk for trial discontinuation. ANN NEUROL 2022;92:729–744
Septin‐5 and ‐7‐IgGs: Neurologic, Serologic, and Pathophysiologic Characteristics
Hinson, Shannon R., Honorat, Josephe A., Grund, Ethan M. , Clarkson, Benjamin D. , Miske, Ramona , Scharf, Madeleine, Zivelonghi, Cecilia , Al‐Lozi, Muhammad, Bucelli, Robert C. , Cho, Tracey , Grell, Jacquelyn A., López‐Chiriboga, A. Sebastian , Levin, Marc S., Merati, Melody, Montalvo, Mayra , Pittock, Sean J. , Wilson, Michael R. , Howe, Charles L. , Budhram, Adrian , Grell, Jacquelyn, Lopez-Chiriboga, A Sebastian , Pittock, S J , Wilson, Michael R , McKeon, Andrew , Howe, Charles L , Cho, Tracey A , Choi, Ellie, Levin, Marc, McKeon, Andrew

Mayo Clinic

Annals of Neurology | August 15, 2022 | Volume: 92 | Issue: 6 | Pages: 1090-1101

10.1002/ana.26482 | PMID 36053822 Get It

Background and ObjectivesWe sought to determine clinical significance of neuronal septin autoimmunity and evaluate for potential IgG effects.MethodsSeptin‐IgGs were detected by indirect immunofluorescence assays (IFAs; mouse tissue and cell based) or Western blot. IgG binding to (and internalization of) extracellular septin epitopes were evaluated for by live rat hippocampal neuron assay. The impact of purified patient IgGs on murine cortical neuron function was determined by recording extracellular field potentials in a multielectrode array platform.ResultsSeptin‐IgGs were identified in 23 patients. All 8 patients with septin‐5‐IgG detected had cerebellar ataxia, and 7 had prominent eye movement disorders. One of 2 patients with co‐existing septin‐7‐IgG had additional psychiatric phenotype (apathy, emotional blunting, and poor insight). Fifteen patients had septin‐7 autoimmunity, without septin‐5‐IgG detected. Disorders included encephalopathy (11; 2 patients with accompanying myelopathy, and 2 were relapsing), myelopathy (3), and episodic ataxia (1). Psychiatric symptoms (≥1 of agitation, apathy, catatonia, disorganized thinking, and paranoia) were prominent in 6 of 11 patients with encephalopathic symptoms. Eight of 10 patients with data available (from 23 total) improved after immunotherapy, and a further 2 patients improved spontaneously. Staining of plasma membranes of live hippocampal neurons produced by patient IgGs (subclasses 1 and 2) colocalized with pre‐ and post‐synaptic markers. Decreased spiking and bursting behavior in mixed cultures of murine glutamatergic and GABAergic cortical neurons produced by patient IgGs were attributable to neither antigenic crosslinking and internalization nor complement activation.InterpretationSeptin‐IgGs are predictive of distinct treatment‐responsive autoimmune central nervous system (CNS) disorders. Live neuron binding and induced electrophysiologic effects by patient IgGs may support septin‐specific pathophysiology. ANN NEUROL 2022;92:1090–1101
Murine CAR19 Tregs suppress acute graft-versus-host disease and maintain graft-versus-tumor responses
Bolivar-Wagers, Sara , Jin, Sujeong , Thangavelu, Govindarajan , Larson, Jemma H. , McDonald-Hyman, Cameron , Aguilar, Ethan G. , Saha, Asim , Koehn, Brent H. , Hefazi, Mehrdad , Osborn, Mark J. , Jensen, Michael C. , Wagner, John E. , Hefazi, Mehrdad , Koehn, Brent , Loschi, Michael L. , Pennell, Christopher A. , Blazar, Bruce R.

Mayo Clinic

JCI Insight | August 2, 2022 | Volume: 7 | Issue: 17 | Pages: No page available

10.1172/jci.insight.160674 | PMID 35917188 Get It

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) efficacy is complicated by graft-versus-host disease (GVHD), a leading cause of morbidity and mortality. Regulatory T cells (Tregs) have shown efficacy in preventing GVHD. However, high Treg doses are often required, necessitating substantial ex vivo or in vivo expansion that may diminish suppressor function. To enhance in vivo suppressor function, murine Tregs were transduced to express an anti–human CD19 chimeric antigen receptor (hCAR19) and infused into lethally irradiated, hCD19-transgenic recipients for allo-HSCT. Compared with recipients receiving control transduced Tregs, those receiving hCAR19 Tregs had a marked decrease in acute GVHD lethality. Recipient hCD19 B cells and murine hCD19 TBL12-luciferase (TBL12 luc ) lymphoma cells were both cleared by allogeneic hCAR19 Tregs, which was indicative of graft-versus-tumor (GVT) maintenance and potentiation. Mechanistically, hCAR19 Tregs killed syngeneic hCD19 + but not hCD19 – murine TBL12 luc cells in vitro in a perforin-dependent, granzyme B–independent manner. Importantly, cyclophosphamide-treated, hCD19-transgenic mice given hCAR19 cytotoxic T lymphocytes without allo-HSCT experienced rapid lethality due to systemic toxicity that has been associated with proinflammatory cytokine release; in contrast, hCAR19 Treg suppressor function enabled avoidance of this severe complication. In conclusion, hCAR19 Tregs are a potentially novel and effective strategy to suppress GVHD without loss of GVT responses.